Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

REGN banks on Dupixent and Eylea HD gains to offset Eylea's decline while oncology wins strengthen its diversified pipeline.

Sanofi (SNY) halts shipments of cholesterol drug Praluent developed with Regeneron (REGN) due to availability issues. Read ...

Sanofi (NASDAQ:SNY) announced on Tuesday that it has stopped supplying Praluent in China due to limited availability of the popular cholesterol medication.

Four out of 10 eczema patients struggle with sleep, and they may not volunteer that information unless you ask.

The Victoria, B.C.-based company is developing EP-104IAR for osteoarthritis pain and a new formulation for eosinophilic ...

In major recent developments, a confidentiality request was rejected, Samsung and its representative A&O Shearman secured a ...

Dupilumab may provide a nonsteroidal option for managing cancer therapy-related skin toxicities, according to a study.

Patients with psoriasis have significantly more difficulty sleeping, particularly in new environments, than matched ...

President Donald Trump has called on 17 pharmaceutical companies to implement most-favored-nation drug pricing in the next 60 days.